On page 5780, in the legend for Figure 2C, the estimated progression-free survival at 48 months should read 70%, not 80%.
. 2023 Oct 31;7(21):6567. doi: 10.1182/bloodadvances.2023011694
Gill S, Vides V, Frey NV, et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 2022;6(21):5774-5785.
Collection date 2023 Nov 14.
© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
PMCID: PMC10692278 PMID: 37889496
This corrects the article "Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia" in volume 6 on page 5774.